Greetings from Texas! Before I begin, let us pause and remember the lives of the fallen police officers in grief-stricken Dallas, victims of the tragic event in Nice and the deaths of innocent people around the world.

As President of the AOCD, I welcome you to this edition of DermLine. I must extend my special thanks to Dr. Rick Lin, our Immediate Past President, who has supported me tirelessly during this term. His friendship and his willingness to share his knowledge have proven invaluable. I also would like to acknowledge the Board of Trustees, Marsha Wise and the entire AOCD team – your support of me has been tireless and humbling.

While writing this brief missive, I am preparing for a trip to Chicago to attend the annual AOA House of Delegates meeting. I am reminded of the great progress we have made in moving the AOCD forward!

A single accreditation system for graduate medical education programs in the United States marks a true milestone in the lives of graduates of osteopathic institutions. Our doctors will now complete their residency and/or fellowship education in ACGME-accredited programs and demonstrate achievement of common milestones and competencies without impediments. It is my hope that osteopathic and allopathic graduates who train together, side by side, will no longer be a divided group.

Our work is not done! As I mentioned in my last message, the AOCD remains a strong organization. I am proud of our heritage and mindful of the work that lies ahead. This great organization has nurtured me throughout my career and will do the same for generations of dermatologists to come – if we believe in and support the AOCD. Please join me in support of and preservation of this magnanimous organization. Dr. Levine, Past President of the American Osteopathic Association from 2011 through 2012 moved me in a profound way. His passion for medicine, particularly the osteopathic approach and philosophy, requires that we “summon the inner DO within us” and deliver that special healing touch that our patients and the public at large so desperately seek. Our gift is in understanding and healing the whole person. Let us not forget our purpose and those we serve!

Dr. Abel Torres, current President of the AAD, and I continue to work closely together to support each other as our individual organizations coalesce in a symbiotic relationship. The AOCD will remain a strong provider of service and support to dermatologists who chose osteopathy in preparation for their professional career. The service we provide through professional development is second to none. Our publications will continue to share information and keep our members up-to-date in current topics of interest. The person-to-person connection is what makes AOCD one of the greatest assets in our daily professional lives.

As you read this edition of DermLine, reflect on the vision of the founding members of the AOCD. It is because of their vision and their struggles that WE all are dermatologists. Our future will remain strong as long as we join together in keeping this vision alive. Keep the main thing the main thing.

I look forward to seeing you in Santa Monica in September!

Alpesh Desai, DO, FAOCD
President, American Osteopathic College of Dermatology
Executive Director’s Report
by Marsha Wise, Executive Director

Hello Everyone,

We’ve had a busy summer here in the AOCD office. We’ve been working diligently on our application for Accreditation Council for Continuing Medical Education (ACCME). By obtaining this accreditation, we will be able to award AMA CME in addition to AOA CME. To receive Provisional Accreditation, which is a 2 year term, the AOCD must comply with ACCME Criteria 1-3 and 7-12. To view this criteria, please visit the ACCME page at http://www.accme.org/requirements/accreditation-requirements-cme-providers/accreditation-criteria.

The AOA House of Delegates recently met in Chicago. Meeting news can be found on the AOA website at http://www.osteopathic.org/inside-aoa/events/annual-business-meeting/Pages/default.aspx.


We currently have three of our residency programs that have received Initial Accreditation from ACGME. They are Botsford Hospital Program in Michigan, Lehigh Valley Health Network Program in Pennsylvania and St. Joseph Mercy Livingston Program in Michigan. Other programs have submitted applications and are awaiting the ACGME to do site reviews.

Our Fall Conference will be held in just a few weeks. Log on to our web site to view our speaker lineup: https://aocd-site-ym.com/events/EventDetails.aspx?id=660049

Future AOCD meetings to save the dates for!

March 29- April 2, 2017
Ritz Carlton Atlanta
181 Peachtree Street, Northeast
Atlanta, GA 30303
Phone: (404) 659-0400 $ 239.00 per night plus tax. Reservations must be booked by February 27, 2017

October 24-28, 2017
Intercontinental, New Orleans
444 St. Charles Avenue
New Orleans, LA 70130
Phone: (504) 525-5566 Toll Free (800) 439-4745 http://www.intercontinental.com/hotels/gb/en/new-orleans/
$229.00 per night plus tax. Reservations must be booked by October 2, 2017

March 19-25, 2018
Hilton West Palm Beach
600 Okeechobee Boulevard
West Palm Beach, FL 33401
Phone: (561) 231-6000 http://www3.hilton.com/en/hotels/florida/west-palm-beach-PBIWPHH/index.html $299.00 per night plus tax. Reservations must be booked by February 21, 2018

The new CME cycle began on January 1, 2016. The CME Guide for Physicians can be found here: http://www.osteopathic.org/inside-aoa/development/continuing-medical-education/Pages/cme-guide.aspx. Please monitor your CME report. The AOA no longer will provide to this information to the AOCD office due to their privacy policy. To manage your CME, contact the AOA at (800) 621-1773, ext. 8262, or send an email to the Customer Resource Center at crc@osteopathic.org.

To report Your CME Credits: Fax your CME credits to (312) 202-8202, Attention: Customer Resource Center, or email attachments to crc@osteopathic.org. Be sure to include your name and AOA ID.

As always, should you have questions or concerns, please do not hesitate to contact the AOCD office. If we cannot answer your question, we will direct you to the person(s) that can.

Thank you for allowing me to be your Executive Director, and I hope to see you in Santa Monica.
We are now accepting manuscripts for publication in the upcoming issue of the *JAOCD*. ‘Information for Authors’ is available on our website at www.aocd.org/jaocd. Any questions may be addressed to the editor at journalaocd@gmail.com. Member and resident member contributions are welcome. Keep in mind, the key to having a successful journal to represent our College is in the hands of each and every member and resident member of our College. Let’s make it great!

- Karthik Krishnamurthy, D.O., FAOCD, Editor
We developed PSI while continuing to work full-time at the hospital. Space was rented in a small building and a few part-time assistants were employed. As word spread about our products, business increased and we moved several times to larger facilities to accommodate our growth. We both retired from the hospital in the mid '90s to manage PSI on a full-time basis. Brian Leary and Rick Sandwick joined Conrad Thompson and Ed Mansfield (co-founders) as partners in January 2005.

Initially, we distributed products mainly in the upper Midwest. Today we distribute throughout the USA and internationally. We are regularly inspected by the FDA and licensed by the Minnesota State Board of Pharmacy as a pharmaceutical manufacturer.

Throughout the evolution of PSI, we have been extremely fortunate in obtaining and keeping employees who are dedicated, have great knowledge and skill, ambition, honesty, talent and loyalty. We consider the employees our “PSI family.”

We are grateful for the support and loyalty we receive from physicians and pharmacists that recommend our products and the patients who benefit from them. It is our intention to continue to manufacture and develop new products in the same manner that we have in the past 35 years.

Elekta
Innovative Solutions: Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders.

Sophisticated Systems & Software: The company develops state-of-the-art tools and treatment planning systems for radiation therapy, including brachytherapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Better Treatments With Patients In Focus: Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and save patient lives.

Genentech
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years.

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline.

Our Purpose: Doing now what patients need next.

We believe it's urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about transforming patients' lives. We are courageous in both decision and action. And we believe that good business means a better world.

That is why we come to work each day. We commit ourselves to scientific rigor, unassailable ethics and access to medical innovations for all. We do this today to build a better tomorrow.

We are proud of who we are, what we do and how we do it. We are many, working as one across functions, across companies and across the world.

Roche
Our Values: The three Roche values—Integrity, Courage and Passion—are core to how we want to behave, as individuals and collectively as an organization.

- **Passion** means we use our drive and commitment to energize, engage and inspire others.
- **Courage** means we are entrepreneurial and thus take risks, reach beyond boundaries and experiment.
- **Integrity** means we are consistently open, honest, ethical and genuine.
These values define fundamental attributes for guiding decisions and actions leading to increased innovation and business performance.

A Member of the Roche Group: Genentech became a member of the Roche Group in March of 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development operates as an independent center within Roche.

Sensus Healthcare
At Sensus Healthcare we are devoted to making a difference in the lives of people who suffer from non-melanoma skin cancer and unsightly keloid scarring. By designing and manufacturing safe and reliable state-of-the-art superficial radiation technology right here in the United States, we are providing compassionate dermatologists and oncologists around the world with a non-surgical treatment option that empowers them to cure patients without compromising patient confidence, dignity or quality of life.

The compact and mobile SRT-100™ is making this standard of care accessible to more patients. Not only does the SRT meet stringent safety requirements set by the FDA, UL and ISO/CE Mark certification, it is backed by accomplished, ethical leadership and scientific case studies that are testaments to the SRT’s exceptional performance.

Medimetriks Pharmaceuticals, Inc.
Medimetriks is a leading independent specialty pharmaceutical company dedicated to the dermatology and podiatry markets. We are committed to advancing patient care through the development, licensing and commercialization of innovative prescription skincare brands that fill unmet needs in the markets we serve. Our current portfolio of brands, which are promoted by our national sales force, treat conditions including acne, rosacea, atopic dermatitis, fungal infections, dystrophic nails and impetigo.

We are experts in commercialization, including creating brands, maximizing life cycles and generating value for biotech, generic and other development companies that may benefit from the depth and breadth of our relationships in dermatology and podiatry.

Officers:
Bradley Glassman is the Chairman and CEO of Medimetriks. Previously, Mr. Glassman was Senior Vice President, Sales and Marketing of Bradley Pharmaceuticals.

R. Brent Lenczycki, CPA, is Medimetriks’ Chief Financial Officer. Prior to joining Medimetriks, Mr. Lenczycki served as Vice President, Chief Financial Officer of Bradley Pharmaceuticals. During his time at Bradley, Mr. Lenczycki also held the positions of Manager of Finance and Purchasing and Vice President, Finance.

Alan Goldstein is the Executive Vice President, Business Development for Medimetriks. Mr. Goldstein served as Vice President, Corporate Development at Bradley Pharmaceuticals.

David Addis is the Senior Vice President of Brand Communication for Medimetriks. At Bradley, Mr. Addis served as Vice President of Creative Services and was responsible for the Company’s advertising, marketing and corporate communications.

Allergan
Leading Growth Pharma: Allergan, plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Open Science: Allergan is an industry leader in Open Science, the company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

16,000 Employees: Our company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

100 Countries: With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

ProPath
ProPath is a team of board-certified pathologists recruited from top-tier medical centers and academic institutions around the country. They are subspecialty-trained experts in the fields of dermatopathology, women’s health, gastrointestinal pathology, hematopathology, immunohistochemistry, pediatric pathology, renal pathology, urologic pathology and molecular diagnostics.

ProPath has surrounded its physicians with an unsurpassed, internationally-recognized laboratory utilizing a proprietary tracking system that focuses on the patient’s biopsy specimen every step of the way. However, ProPath is more than a lab; it is also a medical practice. ProPath’s physicians not only diagnose many rare and complicated cancer cases, but also prevent incorrect diagnoses and treatment.

With a focus on patient safety, ProPath has invested in today’s technological advances to bring results directly into their clients’ systems.

AbbVie
At Abbvie, we have the expertise of a proven pharmaceutical leader and the focus and passion of an entrepreneur and innovator.
DUSA Pharmaceuticals, Inc.
DUSA Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company focused primarily on the development and marketing of its Levlunan Kerastick (aminolevulinic acid HCl) for Topical Solution, 20% photodynamic therapy (PDT) technology platform used in conjunction with its proprietary light source, the BLU-U Blue Light Photodynamic Therapy Illuminator. Levlunan Kerastick in combination with the BLU-U is approved by the U.S. Food and Drug Administration for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. Actinic keratoses is the most frequently diagnosed skin disease by U.S. dermatologists. PDT is a two part process in which the target cells are made extremely sensitive to light and then exposed to blue light, which destroys the cells. The BLU-U, as a standalone device, uses light to treat mild to moderate inflammatory acne. DUSA is based in Wilmington, MA.

Celgene
Committed to improving the lives of patients worldwide: At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.

Aurora Diagnostics
Aurora Diagnostics is the largest independent anatomic pathology laboratory company in America, providing unsurpassed diagnostic and information services to physicians, hospital systems and researchers. Our focus on providing unsurpassed diagnostic, prognostic and therapeutic information and services to every healthcare community we serve, is driven by our belief that the practice of medicine and the delivery of health care are both personal and best delivered locally. We currently operate over 20 community-based laboratories in the United States, with over 150 licensed physicians on staff to service dermatologists, OB/Gyn professionals, family practitioners, gastroenterologists, urologists, general surgeons, oncologists and over 65 community-based hospitals.

We partner with medical professionals in the local communities we serve in order to deliver the highest quality information and care for their patients. Our physicians are members of the local medical communities we serve — physicians who are personally known to our referring physicians and with whom the latter may immediately confer regarding patient care. Our personalized approach means that our referring physicians experience the highest quality, customized, services available within their local medical communities. Our expertise in integrating relevant technologies ensures that physicians and their patients consistently have access to best possible clinical information.

Aurora’s commitment to serving the unique needs of referring physicians, coupled with our personalized approach, have created a reputation of excellence within our locally supported communities. Our community-based physician practices and laboratories include some of the most well-established practices and most renowned experts in our field — specialists who are known for their clinical contributions and dedication to physician education to further the field of medicine.

Our referring physicians receive more than mere diagnostics laboratory services. Aurora provides a holistic approach to our relationship with each referring physician. We provide a wide range of specialized services, tools and innovative technology solutions to enhance each physician’s practice and support his/her ability to deliver optimal patient care.

Cedars-Sinai Pathology & Lab Medicine
Since its beginning in 1902, Cedars-Sinai has evolved to meet the healthcare needs of one of the most diverse regions in the nation, continually setting new standards in quality and innovation in patient care, research, teaching and community service.

Today, Cedars-Sinai is widely known for its national leadership in transforming healthcare for the benefit of patients.

Cedars-Sinai is one of the largest nonprofit academic medical centers in the U.S. with 886 licensed beds, 2,100 physicians, 2,800 nurses and thousands of other healthcare professionals and staff. Clinical programs range from primary care for preventing, diagnosing and treating common conditions to specialized treatments for rare, complex and advanced illnesses. In addition, Cedars-Sinai serves the community through its Medical Network, which includes the highly-rated Cedars-Sinai Medical Group and Cedars-Sinai Health Associates.
From hard-to-reach spots to large body areas...

WE’VE GOT YOU COVERED

The Only Triamcinolone in an Aerosol Spray

Available in 63 g and 100 g sizes

Indication:
Kenalog® Spray (triamcinolone acetonide topical aerosol, USP) is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Important Safety Information:
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS, Pediatric Use).

You are encouraged to report negative side effects of prescription drugs to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

For topical use only. Please see adjacent page for full prescribing information.

For more information, visit www.kenalogspray.com

Reference:
2. After spraying, the nonvolatile vehicle remaining on the skin contains approximately 0.2% triamcinolone acetonide. Each gram of spray provides 0.147 mg triamcinolone acetonide in a vehicle of isopropyl palmitate, hydrated alcohol (10.3%), and iso-butane propellant.
Cedars-Sinai has consistently been named one of America’s Best Hospitals by U.S. News & World Report, has received the National Research Corporation’s Consumer Choice Award 18 years in a row for providing the highest quality medical care in Los Angeles and has the longest running Magnet designation for nursing excellence in California.

Cedars-Sinai is a leader in the clinical care and research of heart disease, cancer and brain disorders, among other areas. Pioneering research achievements include using cardiac stem cells to repair damaged hearts, developing minimally invasive surgical techniques and discovering new types of drugs to target cancer more precisely.

Cedars-Sinai also impacts the future of healthcare through education programs that encompass everything from highly competitive medical residency and fellowship programs to a biomedical science and translational medicine PhD program, advanced training for nurses and educational opportunities for allied health professionals. Most notably, Cedars-Sinai demonstrates a long-standing commitment to strengthening the Los Angeles community through wide-ranging programs that improve the health of its most vulnerable residents.

Cleveland Skin Pathology Laboratory, Inc.
Cleveland Skin Pathology (CSP) was founded by Dr. Jerome R. Pomeranz in 1972. At that time, he was Chairman of the Department of Dermatology at MetroHealth Medical Center in Cleveland, OH and an Associate Professor of Dermatology and Pathology at Case Western Reserve University School of Medicine. Highly respected by his colleagues, who often sought his expert opinion on cutaneous disease, he recognized the need for an independent laboratory solely dedicated to diagnosing skin disease. As the laboratory has grown over the years, it is now comprised of six board-certified dermatopathologists, who are also board-certified in pathology or dermatology.

The dermatopathologists at CSPL are physicians who had fellowship training at completely different academic institutions throughout the United States. This allows for a unique combination of strengths in various aspects of dermatopathology, such as hair pathology, lymphomas, pediatric dermatopathology and immunodermatology. Practicing in a collaborative environment with daily discussion of difficult cases, the dermatopathologists at CSPL are also always available to discuss cases with referring clinicians.

A unique service available to all referring clinicians is that five of the dermatopathologists are actively practicing dermatologists in an academic setting and are able to provide their clinical input and expertise.

3Gen Inc.

3Gen, Inc. introduced the concept of polarized light dermoscopy in 2001 with the introduction of the DermLite DL100. Since then, 3Gen has become the world’s leading seller of dermascopes. With options for image capture via phone, tablet or camera and integration with many EMR programs, the DermLite brand offers you a seamless way to help increase the odds of making the correct diagnosis of suspicious skin lesions.

Novartis
Novartis Pharmaceuticals is a division of Novartis AG, with global corporate headquarters in Basel, Switzerland. We have 52,700 employees in 107 countries that are helping patients in 140 countries. We focus our efforts and expertise in seven disease areas and our goal is large in scope but simply stated: we work to discover new ways to improve and extend people’s lives.

We work closely with over 800 patient advocacy organizations, multiple leading research institutions and other key stakeholders around the world to enhance our science-based innovation and deliver these life-saving treatments to people who need them.

LEO Pharma
LEO Pharma is a leading global pharma company specializing in dermatology and critical care. For more than a century, our products have improved millions of people’s lives around the world.

Headquartered in Denmark, we have employees in 61 countries and our products are sold in more than 100 countries. To realize our vision of becoming the world’s leading specialty pharma company within our focus...
areas, we are expanding into new regions and markets, reaching more patients and societies with competitive drugs and therapies that address unmet medical needs.

**Encore Dermatology**
Headquartered in Malvern, PA, Encore Dermatology is a privately held fully-integrated dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients.

**Galderma**
Just as the skin is a unique system within the human body, dermatology requires specialized knowledge and unique skills. Galderma was founded with the goal of establishing a pharmaceutical company exclusively focused on dermatology.

For over 30 years, all our resources have been channeled in a single direction: to provide innovative medical dermatological solutions that meet the needs of patients and physicians with a particular focus on acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis (fungal nail infections), pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The skin conditions we treat can have strong psychological and social implications in the everyday lives of our patients. By treating these conditions, we help people preserve, restore and maintain healthy skin and improve their quality of life.

Today, Galderma is a global dermatology company partnering with healthcare professionals to provide innovative medical solutions to patients with skin health needs. The company has 34 wholly-owned affiliates and a worldwide network of distributors, over 6,000 employees and an extensive product portfolio available in more than 100 countries.

Galderma's R&D is continually dedicated to finding new medical solutions, offering physicians more options and offering patients a better quality of life. Five state-of-the-art R&D centers and six manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy.

**Bayer**
Bayer is a world-class innovation company with a more than 150-year history and core competencies in the fields of health care and agriculture. We develop new molecules for use in innovative products and solutions to improve the health of humans, animals and plants. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms.

With our products, we are contributing to finding solutions to some of the major challenges of our time. The growing and increasingly aging world population requires improved medical care and an adequate supply of food.

Bayer is improving people’s quality of life by preventing, alleviating and curing diseases. And we are helping to provide a reliable supply of high-quality food, feed and plant-based raw materials.

Our goal is to achieve and sustain leadership positions in our markets, thus creating value for our customers, stockholders and employees. To this end, our strategy is designed to help solve some of the most pressing challenges facing mankind, and by doing this exceptionally well, we aim to strengthen the company’s earning power.

Our **LIFE** values: We are committed to operating sustainably and to addressing our social and ethical responsibilities as a corporate citizen, while at the same time respecting the interests of all our stakeholders. Employees with a passion for innovation will enjoy excellent development opportunities at Bayer. Our values play a central role in our daily work and are intended to guide us in fulfilling our mission. These values are represented by the word **LIFE**.

The word **LIFE** doubles up as an acronym for Bayer’s key values and leadership principles. **LIFE** stands for Leadership, Integrity, Flexibility and Efficiency.

These values apply to everyone at Bayer and are firmly integrated into our global performance management system for managerial employees. Our value culture ensures a common identity within the enterprise across national boundaries, management hierarchies and cultural differences.

**Aclaris Therapeutics, Inc.**
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in dermatology. Our lead drug candidate A-101 is being developed as an in-office treatment for seborrheic

---

**Lilly USA, LLC to Host Product Theater at AOCD Fall Meeting in Santa Monica**
Lilly is delighted to host a promotional educational product theater facilitated by Dr. Michael Heffernan from San Luis Obispo, CA on September 15th from 4:30-5:30 PM. Dr. Heffernan comes to AOCD to lecture with a wealth of experience in community, academic and research-based environments. He received his undergraduate degree from the University of Notre Dame, his medical degree from the University of Michigan and trained in dermatology at Stanford, where he was chosen to be chief resident. Dr. Heffernan then served our country in the Air Force. After returning from service, he taught at Washington University and Wright State University, where he also served as Chairman of the Department of Dermatology and Residency Program Director. Dr. Heffernan’s research has led to the development of dozens of medications. Dr. Heffernan is an internationally-recognized dermatologist for problems ranging from the common to the complex.
keratosis (SK), a common non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.

In September 2015, Aclaris acquired a portfolio of oral and topical Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions.

Aclaris was founded in 2012 and is headquartered in Malvern, PA. The company is led by a management team with rich experience and expertise in dermatology and dermatologic drug development.

**Valeant**

Our Mission: Valeant Pharmaceuticals International, Inc. is a diverse and decentralized pharmaceutical company that is committed to focusing on our key stakeholders while delivering consistently high performance. Our values provide the overall direction for our company and provide us with the tools necessary to rise to any challenge by leveraging our collective hard work and effort along with our unwavering competitive spirit. These values help us set goals based on our organization's potential and what we hope it will become.

Our Values: The following values are essential to realizing our mission as an organization.

- **Ethics**: Our most important objective is to serve our stakeholders, including the patients and consumers who use our products, the physicians who prescribe/recommend them and the customers who provide retail outlets for these products.
- **Accountability**: We drive performance and take responsibility to deliver on our duties and promises to our stakeholders.
- **Creativity and Entrepreneurship**: We constantly search for new ways to do things better while creating value.
- **Resourcefulness**: We work best as a lean, high-performing workforce and invest in resources only where it makes business sense to do so.
- **Speed**: We make decisions and work quickly without sacrificing execution.
- **Transparency**: We share information openly and communicate directly.
- **Teamwork and Talent Development**: We strive to build the best team in the industry by investing in one another.

**Advanced Dermatology & Cosmetic Surgery**

Advanced Dermatology and Cosmetic Surgery is the largest dermatology practice in the country with over 150 locations. We are committed to providing comprehensive and unparalleled dermatologic care in a welcoming and engaging environment. We seek to make each patient experience unique by combining superior patient safety and privacy standards in treating dermatologic and cosmetic concerns. We strive to combine the best of the art of medicine with the latest advances in research and technology in formulating individualized treatment plans to achieve a unique, desired and aesthetically pleasing result.

**Philosophy: Advanced Dermatology and Cosmetic Surgery**

practices under several premises as it relates to your experience as a patient in our practice.

**Patient Safety**: Your safety is our highest priority. We are committed to well-educated and trained staff to exceed current standards for patient safety. We employ board-certified dermatologists, fellowship trained Mohs surgeons, board-certified and fellowship trained plastic surgeons and highly trained and supervised mid-level providers as a commitment to patient safety.

**Patient Experience**: We want to make your visit the best ever. We hope to elevate the bar in delivering an authentic patient experience. We strive to treat every patient with respect, value and privacy. We feel privileged that you have entrusted your care with us and we take that responsibility very seriously.

**Patient Education & Communication**: Our hope is that you will gain a new appreciation of your dermatologic and cosmetic concerns. Our goal is to explain treatment options, risks, benefits and alternatives of treatment for each of your concerns. Patient education leads to treatment success. Your care does not end once you leave our clinic, it continues with complete follow-up care.

**Medical Advances**: We strive to offer the latest procedures and technological advances to all our patients.

**Mayne Pharma**

Mayne Pharma Group Limited (Mayne Pharma) is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 125 clients worldwide.

Mayne Pharma’s roots can be traced to FH Faulding and Co., for many years one of the largest and most prominent public companies headquartered in South Australia.

A technology driven company, Mayne Pharma has a significant product portfolio and pipeline, global reach through distribution partners in Australia, North America, Europe and Asia and two product development and manufacturing facilities based in Salisbury, Australia and Greenville, NC, USA with expertise in formulating complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds. The business is supported by over 600 staff globally with more than 180 scientists employed.
Passion to Heal (ME to WE Trips Inc.)
Passion to Heal™ provides American dermatologists and dermatology practitioners with the opportunity to travel on a fully-funded ME to WE Trip to rural Kenya or India to help transform health care for thousands of adults and children in our charity partner’s communities. Through leveraging their professional expertise and skills, they treat and educate community members and train local clinicians to create sustainable health care solutions. In collaboration with ME to WE Trips, the Passion to Heal™ initiative funds the cost of these medical volunteer trips, supported by Valeant Pharmaceuticals NA LLC (VPNA).

DLCS
DermPath Lab of Central States (DLCS) is a full-service dermatopathology laboratory founded in 1984 by Dr. Tom Olsen. Our team of highly trained board-certified dermatopathologists has been serving physicians and patients for over 30 years. As a national leader in skin pathology, we stand by our commitment to quality, efficient service and education – all essential to our dedication to patient care.

Our technical team incorporates the newest developments in advanced and molecular testing into our laboratory. DLCS invests significant resources into technology such as digital pathology and lab software systems to provide unparalleled security and efficiency.

DLCS serves as a teaching facility for Wright State University’s Boonshoft School of Medicine. Our physicians serve on the faculty at various local universities and provide virtual teaching programs for residency programs nationwide.

Sun Pharma
Sun Pharma is amongst India’s largest and fastest growing pharma companies. India and the U.S. account for almost 80% of our business. In India, we’re market leaders in six therapies, such as cardiology and psychiatry, with trusted brands and effective marketing teams. In the U.S., we’re a fast growing generic company, with 250 products approved and presence across dermatologicals and controlled substances. Our global manufacturing base spans 23 sites across continents. We’re one of the largest spenders on generic R&D.

NOW AVAILABLE.

Visit Our Booth to learn more about Taltz
Dear Colleagues,

Greetings from your AOCD resident liaison! Summer is here! Hello sunshine and SPF!! Our warmest congratulations go out to all of our recent graduates. You reached your dreams and we are all so proud of you. It’s your time to shine! We wish you the best of luck on your upcoming AOBD certifying examination held on Saturday, September 17, 2016, at the Loews Santa Monica Beach Hotel, AOCD Fall Meeting in Santa Monica, California. This meeting is not required for current residents, but is strongly encouraged. I would also like to welcome all of our new first year residents. By now hopefully you have had a little time to get your feet wet in starting your dermatology residency. I know you have waited a long time for this and now it’s finally here! First year can be tough and the learning curve is huge, but remain focused and study hard! Lean on your co-residents for support. Dermatology residency, while challenging, is a very special time of our lives. Remember to appreciate this moment, and make it great! We are only residents once.

- **In-Training Examination Reminder**
  - The AOCD will NOT be giving an in-training examination for the 2016-2017 academic year. In its place, all residents will be required to take the 2017 ABD In-Training Exam. Registration begins November 2016. The AOCD will give a supplemental essay portion, which will cover the Osteopathic component.
  - Great study tools are: Derm-In Review and Jain Dermatology Study Guide and Comprehensive Board Review
  - **ATTENTION:** MERZ sponsorship will end after the August Board Exams!
  - Please help secure a new sponsor by signing the petition at: [http://dermatologyinreview.com/Merz](http://dermatologyinreview.com/Merz)
  - **2017 AOCD Spring Meeting – Atlanta, GA, March 29-April 2**
  - Resident attendance is **required** for all Spring Meetings.
  - For our upcoming Spring Meeting in Atlanta, GA, resident lectures will take place on Wednesday, March 29. Stay tuned for your assigned topic. I wish all programs the best in putting together future presentations!
  - The presentation of resident awards will take place at this meeting as well.

- **All residents**
  - Be sure to keep your patient logs, including segregated totals and consultations, updated as this will make submitting your Annual Report much easier
  - Remember that at least once in your residency you must submit an abstract to the Gross and Microscopic Symposium held by the American Academy of Dermatology (AAD). This cannot be anything that was previously published or submitted for publication.
  - Second year residents are required to submit an electronic poster at an AOCD meeting. This can be from a previously published or submitted work, including the AAD symposium.
  - Second and third year residents, if you are considering applying for a fellowship, I encourage you to consider one of the many fellowship opportunities offered by the AOCD, including Mohs, dermatopathology and pediatrics. Information can be found on our website at [www.aocd.org](http://www.aocd.org)

- **Newly matched residents**
  - Please be sure to submit your resident file packet including: AOCD Resident Membership Application, 2016 AOCD Membership Dues Payment, Passport Sized Portrait Photo, Current CV, Medical School Diploma, Internship Diploma and State Medical License

**ACGME Accreditation: Osteopathic Focus**

As we all move towards ACGME accreditation, it is important to remember one way we can all preserve our osteopathic distinction is by applying for Osteopathic Focus. I strongly encourage all to do this. Our allopathic colleagues also have the option to apply for Osteopathic Focus. For those of us currently working on our application, our ACGME ADS support contact is Kevin Bannon. [webads@acgem.org](mailto:webads@acgem.org). 312-755-7111.

**Dimensional Dermatology**

I would like to inform all of you about a brand new blogging website called **Dimensional Dermatology**, founded in May 2016 by Dr. Paul M. Graham, a senior dermatology resident at St. Joseph Mercy Dermatology in Ann Arbor, Michigan. This website provides concise, up-to-date, easy to read articles on varying topics in general, surgical and cosmetic dermatology as well as aesthetic medicine, cosmeceuticals and plastic surgery. Several of our AOCD resident colleagues are regular authors for this blog including myself; Bridget Mcllwee, DO; Gabriela Maloney, DO and Collin Blattner, DO. This blog is built upon the concept of digesting complicated research data, technologies, procedures and innovative treatments into succinct, easy-to-read articles with the target audience focusing on the general public, consumers, patients, medical staff and providers. I welcome all of you to check this out at [https://dimensionaldermatology.com/](https://dimensionaldermatology.com/). If anyone has an interest in contributing to Dimensional Dermatology, please contact Paul M. Graham, DO at dimensionaldermatology@gmail.com. I invite all of you to follow us on Facebook [@dimensionaldermatology](https://www.facebook.com/dimensionaldermatology) and Twitter [@dimensionalderm](https://twitter.com/dimensionalderm).

In conclusion, I hope this column finds you well and you all are enjoying yet another wonderful year in dermatology residency! I want to thank you for allowing me to advocate for all of our osteopathic dermatology residents this year. It is now time to start thinking about nominating your next AOCD Resident Liaison!! Please send nominations to [aocdrresident.connection@gmail.com](mailto:aocdrresident.connection@gmail.com).
For eczema-prone skin

TWO ADVANCED TECHNOLOGIES.

HYDRATE

ONE REPLENISHING REGIMEN.

Cetaphil® RestoraDerm® products are the first and only regimen with advanced ceramide and Filaggrin technology™

To help restore the skin barrier in dry, eczema-prone skin, recommend the Cetaphil® RestoraDerm® regimen.¹

Hi everyone,

I would like to take the opportunity to congratulate our recently graduated residents and wish you all well in your future plans and endeavors. It has been great working with you all over the past three years. It’s also time to welcome new residents joining us for the 2016-2017 year. I wish all of you the best of luck in this next exciting step of your medical careers. If there is ever any way I can help you, you are always welcome to contact me by email or phone. I’m here to help!

Documentation needed for new residents

New residents who began training in July 2016 should submit all of their application materials to the national office. Dues should be paid at this time, if payment has not been made this year. Those who have already paid student dues for the current year owe a balance of $25. If you are uncertain if you have paid this year, please feel free to contact me.

All residents are asked to provide the following documents:

- A copy of your medical school diploma (and exact date of graduation)
- A copy of your internship diploma (exact dates of attendance and name and address of school)
- A copy of your state license
- 2 passport size photos
- A current CV

Incoming Residents for 2016-2017

I have a few additions to our incoming resident lineup for 2016-2017. Nady Hin, DO; Michael Lipp, DO and Rachel White, DO are the first residents training in the new LECOMT/Larkin Community Hospital – Palm Springs Campus program under the direction of Bradley Glick, DO, FAOCD. With the addition of these residents, the incoming class of residents grows to 58—the largest class in the history of the AOCD. This brings the total number of residents in 32 AOCD programs to 163.

2016 Dermatologic Surgery in the Outback Paper Competition

Dr. Anthony Dixon, an Australian surgeon who specializes in skin cancer surgery, has been gracious enough to extend an invitation to the physicians and residents of the AOCD for a preceptorship “down under.” The preceptorship is limited to two physicians each year. One resident and one attending physician (AOBD board eligible or board-certified) will be selected for the preceptorship.

The resident selection is based on a surgical paper competition. All residents wishing to have the chance to go can prepare a surgical paper. This paper would be judged on the basis of its surgical application in dermatologic surgery, with an emphasis on cutaneous cancer. The paper should be based on principles of surgical treatments for skin cancer with emphasis on literature review and/or new techniques, with original research strongly encouraged.

The AOCD Awards Committee along with Dr. Dixon will select the winning author. Participation in this competition is limited to second and third year residents only. The deadline for entry is September 16, 2016.

Submissions should be sent to the AOCD office in Kirksville. The winner would receive approximately $1,500 towards the cost of the trip to Australia, with additional funding to be determined on proceeds generated by the silent auction. This would not cover the cost of the entire trip but would pay a substantial portion of it. The approximate airfare is $1,200. Attending physicians are responsible for their own expenses.

Winners can essentially schedule their preceptorship for any time of year, pending no conflicts with Dr. Dixon’s schedule.

Confessions of a Dermatology Resident

By Laura Jordan, DO

Counting down the days until July 1, the day that felt like it would never arrive is quickly approaching and excitingly petrifying. How strange it is to be on the other side of questions now... “Laura, are you excited to start derm? Can you let me know if you have any interesting cases to write up? When should I submit my application? Who should I ask to write my letters?...”

Somehow by reaching that unattainable ethereal title of “Dermatology Resident” rumors circulate that you know what you’re doing, that your words are drops of gold leading the way to acceptance. A rarely acknowledged fact though: I followed the same gold-flecked trail of my predecessors, and I am merely offering refurbished, buffed out advice that seemed to “work for me,” but really what “worked” was nothing in particular. It was trying to be yourself despite the audition setting and working well with those around you. I was given similar advice on multiple occasions, but, like many of my “dermabees,” I just knew there had to be something more, something tangible I could provide at my dermatology auditions. So while I now herald the “be yourself” headline, I realize deep down the advice that will stick with my dermabees is the advice they can grip. Because the scariest thing about being yourself is accepting the idea that someone may not like you.

Now that I can count the days down using merely my fingers until the start of my residency, the bubbling excitement remains but with an overlay of what I’m told are “healthy” nerves. A feeling I’m sure my fellow first year dermies share.
Answers To Frequently Asked Questions About AOA CME Requirements

Q. What are the dates of the current CME Cycle?

Q. What are the CME requirements of the AOA?
A. AOA members are required to obtain 120 credit hours in a three-year cycle, with at least 30 credits in Category 1-A. The remaining 90 credits may be obtained in Categories 1-A, 1-B, 2-A, or 2-B.
B. Osteopathic board certified physicians must earn at least 50 of their total 120 credits in their primary specialty.

Q. Can I submit CME credit now to apply to future CME Cycle requirements?
A. No. Credits acquired during this cycle cannot apply to future CME requirements. If the date of the activity reflects attendance from a previous cycle, those credits will not be applicable toward the physician’s current CME requirement.

Q. I recently completed my residency or fellowship. How does this affect my AOA CME requirements?
A. Yes. CME programs which are sponsored by an AMA-accredited Category 1 CME sponsor and meet the 1-A faculty/hours requirement for AOA Category 1-A credit.
B. Risk management programs will be granted Category 2-A credit if they are clinical in nature, sponsored by an AOA-accredited Category 1 CME sponsor, and meet the 1-A faculty/hours requirement for AOA Category 1-A credit.

Q. What is the policy for awarding CME credit for risk management programs and the total number of credits permitted per CME cycle?

Risk Management Programs
A. Risk management programs will be granted Category 1-A credit if they are clinical in nature, sponsored by an AOA-accredited Category 1 CME sponsor, but do not meet the 1-A faculty/hours requirement for AOA Category 1-A credit.
B. Risk management programs will be granted Category 2-A credit if they are clinical in nature sponsored by an AOA-accredited Category 1 CME sponsor, and meet the 1-A faculty/hours requirement for AOA Category 1-A credit.
C. Risk management programs will be granted Category 1-B credit if they are administrative, sponsored by an AOA-accredited Category 1 CME sponsor.
D. Risk management programs will be granted Category 2-B credit if they are administrative in nature and are provided by an AOA-accredited Category 1 CME sponsor.

Q. What is the policy for awarding CME credit for managed care programs and the total number of credits permitted per CME cycle?

Managed Care Programs
• Managed care programs will be granted Category 1-A credit if they are sponsored by an AOA-accredited Category 1 CME sponsor and meet the 1-A faculty/hours requirement for AOA Category 1-A credit.
• Managed care programs will be granted Category 1-B credit, if they are sponsored by an AOA-accredited Category 1 CME sponsor and the program does not meet the AOA Category 1-A faculty/hours requirement.
• Managed care programs will be granted Category 2-A credit if they are sponsored by an AOA-accredited Category 1 CME sponsor and the program does not meet the AOA Category 1-A faculty/hours requirement.
• A maximum of five CME credits may be earned for managed care programs.

Q. May I earn credit for postgraduate education programs?
A. Yes. Recertification and Continuing Education (CME) programs related to postgraduate education may be applicable toward the physician’s current CME requirement. For additional information, please refer to the AOA CME Guide (Pages 9-10).

Q. What is my CME requirement for state licensure?
A. CME requirements for state licensure differ between states. Please contact the appropriate state licensing board for more information.

Q. Are Life Members required to fulfill the AOA CME requirements?
A. Yes, AOA Life members in active practice are not exempt and must fulfill the CME requirement.

Q. May I earn CME credit for participating in activities for CME on the Internet?
A. Osteopathic physicians may earn up to 15 credits of their Category 1-A requirement from real time interactive Internet CME, e.g., live programs per CME cycle. For additional information, please refer to the AOA CME Guide (Pages 9-10).

Q. May I earn credit for osteopathic preceptoring?
A. Osteopathic physicians serving as preceptors/GME faculty in any AOA approved osteopathic or ACGME-accredited medical education program may be granted Category 1-B credit. A maximum of 60 AOA Category 1-B credits for faculty/preceptoring may be applied to the 120-hour requirement per CME cycle.

Osteopathic physicians who serve as core clinical faculty for graduate medical education programs, regardless of the institutional residency affiliation, may be granted Category 1-B credit. To obtain credit for faculty and core faculty, the institution/hospitals the Program Director or Director of Medical Education must provide a signed evaluation of the physician’s participation to the AOA Department of Client and Member Services verifying the teaching activity.

No credit is available for preceptoring physician assistants or nurse practitioners.

Q. Does the AOA grant CME credit for allopathic-sponsored programs?
A. Yes. CME programs which are sponsored by an ACCME accredited provider for AMA PRA Category 1 Credit”; approved by the American Academy of Family Physicians (AAFP), or approved by an internationally known sponsor acceptable.

**Continuing Education (CME) Policy**
For additional information regarding specialty CME for managed care programs.

Please refer to the “AOA Specialty Continuing Education (CME) Policy” for additional information regarding specialty CME for managed care programs.
Dr. Papadeas Named One of Denver’s “Top Doctors”

Dr. Gregory G. Papadeas, DO, FAOCD, FAAD, past president of the Colorado Dermatologic Society and the American Osteopathic College of Dermatology, was selected by colleague physicians as one of Denver’s “Top Dermatologists,” as reported by 3280 Magazine. Physicians surveyed, were asked who they would trust most for their dermatologic needs for themselves and their families.

AOCD Student Member Publishes Twice in July

This summer has proved productive for one AOCD student member. Shane Swink, MS, a third-year medical student at Philadelphia College of Osteopathic Medicine (PCOM) was published not once, but twice, in July. He co-authored both articles with Leslie Castelo-Soccio, MD, PhD.

The first article entitled “Red Scaly Eruption in an Otherwise Healthy Two-Month-Old Boy” appeared in the Clinical Challenge section of Volume 170, Issue 7 of JAMA Pediatrics. The article can be found by using the following link: http://archpedi.jamanetwork.com/article.aspx?articleid=2529194

The second article entitled “Loose Anagen Syndrome: A Retrospective Chart Review of 37 Cases” was published by Pediatric Dermatology. The article can be found by using the following link: http://onlinelibrary.wiley.com/doi/10.1111/pde.12912/abstract

Look What’s New on the AOCD Dermatologic Disease Database

Have you checked out the AOCD Dermatologic Disease Database lately? This is a great resource for your patients. Content is prepared by our own AOCD members. Take a look at some of the most recent articles: Apremilast, Brachioradial Pruritus, Eczema Herpeticum, Keratitis Follicularis, Spinulosa Decalvans, Kyries Disease, Meralgia Paresthetica, Notalgia Paresthetica, Orange Palpebral Spots, Parasporiasis, Pemphigoid Gestationis, Secukinumab & Tinea Incognito.

to the Council on Continuing Medical Education (CCME) are eligible for Category 2 credit through the AOA. To obtain the Category 2 credit, please email, fax or mail certificates of attendance to the AOA Department of Client and Member Services.

Q. Does the AOA grant Category 1-A credit for Standardized Life Support Courses or Bioterrorism Courses? A. Yes. Standardized Life Support courses are eligible for a maximum of eight credits of Category 1-A per CME cycle. Any remaining credits left over after the initial eight have been awarded will be recorded as Category 1-B. Online standardized courses will be awarded CME credit for the practical part only.

Bioterrorism courses are eligible for Category 1-A credit up to a maximum of eight credits per three year CME cycle. The remainder of credits will be awarded Category 1-B CME credit. Self-study or home study courses are not eligible for 1-A or 1-B credit.

Q. How is CME credit awarded? A. CME is generally awarded on an hour-for-hour basis. However, physicians may earn a ½ credit per issue for each medical journal read or audiotape listened to, and may earn five credits per medical textbook read during a cycle.

Q. Where can I obtain CME forms for reporting CME credit to the AOA? A. CME Reporting Forms can be found on our website: www.osteopathic.org/inside-aoa/development/continuing-medical-education/Pages/cme-reporting-forms.aspx

Q. Where can I obtain a copy of the CME Guide for Osteopathic Physicians? A. The CME Guide may be found on AOA’s website: www.osteopathic.org/inside-aoa/development/continuing-medical-education/Pages/cme-guide.aspx

Q. What are the email, mailing address and fax number for reporting CME activities? American Osteopathic Association AOA Department of Member and Client Services

Customer Resource Center
142 E. Ontario St.
Chicago, IL 60611-2864
Fax: 312-202-8202
Email: crc@osteopathic.org

For additional information or questions not answered in this FAQ, AOA’s Customer Resource Center (CRC), at (800) 621-1773, option 1, is available for assistance.

Board and Specialty Certification
Q. What is the CME requirement for certified physicians? A. AOA Board Certified Physicians Physicians who are board certified are required to earn a minimum of 50 CME credits within their specialty in each three-year CME Cycle. These credits may be earned in Category 1 or Category 2. (Please see your Specialty Board for clarification.) Certification of Added Qualification (CAQs): For osteopathic physicians holding certification(s) of added qualification (CAQs), a minimum of 25% of the credits (13 credits) must be earned at the level of the CAQ. At least 30% (15 credits) must be earned in the primary certification. CME sponsored by osteopathic specialty affiliates in the individuals declared specialty, will be applied to this requirement on an unlimited hour-by-hour basis.

ABMS Board Certified Physicians Physicians who are both AOA and ABMS board certified are required to earn the same specialty CME credit hours as DOs who are AOA board certified only.

Physicians who are solely certified in an ABMS specialty are required to obtain a minimum of 10 Category 1-A credits in AOA sponsored CME programs during each three-year CME cycle to meet AOA specialty requirement.

Physicians who are solely certified through the ABMS must meet the 120 hour AOA membership requirement.

Please contact your certifying board for information regarding the use of preceptoring or other credits towards
this requirement. Osteopathic physicians may refer to the “AOA Specialty Continuing Education (CME) Policy” for additional information regarding specialty CME program requirements.

**NOTE:** Under current AOA policy, failure to meet the AOA specialty CME requirement is interpreted as a failure to meet the individual physician’s CME requirement. This could result in the loss of AOA membership and in turn result in the possible loss of certification.

**Q. What is the policy for granting Category 1-A credit for non-osteopathic programs accredited by the ACCME or approved by the AAFP, for AOA members that hold certificates for specialties or subspecialties with less than 300 certificate holders?**

A. In recognition of AOA members who hold specialty or subspecialty certificates in specialties with less than 300 certificate holders may have difficulty accruing the necessary AOA 1-A credits required for membership, such members may apply AMA PRA Category 1 Credit™ or AAFP Category 1 credits to their AOA 1-A credit requirement up to the maximum of 15 CME credits per CME cycle to meet the Category 1-A credit requirement for membership.

To qualify for AOA Category 1-A CME credit under this policy the following criteria must be met:

A. Osteopathic physicians must be a member of the AOA.
B. Physicians must be AOA or ABMS certified.
C. The specialty/subspecialty must be listed as a qualifying specialty.

**NOTE:** Lists of specialties and subspecialties with less than 300 certified members are available on the AOA’s website at Osteopathic.org (Click Here To View). This exemption only applies to the 30 Categories 1-A CME credits required for membership in the AOA.

**CME Activity Reports**

**Q. How can I check my CME status or obtain a copy of my CME report?**

A. AOA members may view their CME reports by going to the AOA’s website: clicking on the View My CME Report; and logging in with their AOA ID number or username and password. Members may also contact AOA’s Customer Resource Center (CRC) at (800) 621-1773, option 1, to have their report emailed or faxed. CME reports are free of charge and available to AOA members only.

**Q. What should I do if I’ve never created an account to view my CME Activity Report?**

A. Members who have not created an account to view their CME Activity Report should contact the AOA’s CRC at (800) 621-1773, option 1, to receive a password.

**Non-Qualified CME Activities**

**Q. What programs are ineligible to receive AOA CME credit?**

A. The following are ineligible for AOA CME credit:

No credit is available for preceptoring physician assistants or nurse practitioners.

Though the AOA applauds volunteer work, such work does not qualify for CME credit. Studies completed in the quest for advanced degrees such as Master’s or Doctorate, do not qualify for CME credit. Touring medical facilities does not qualify for CME credit.

**Obtaining 1-A Credits**

**Q. How can I obtain AOA Category 1-A credit?**

A. Category 1-A credit may be earned by attending formal, face-to-face osteopathic programs that are sponsored by AOA-Accredited Category 1 CME Sponsors. A list of AOA Category 1 CME Sponsors may be found on our website: [http://www.osteopathic.org/inside-aoa/accreditation/Pages/cme-sponsor-accreditation.aspx](http://www.osteopathic.org/inside-aoa/accreditation/Pages/cme-sponsor-accreditation.aspx).

For a listing of upcoming programs that are eligible for Category 1-A credit, please refer to the AOA Calendar of Events located on our website: [www.osteopathic.org/Calendar](http://www.osteopathic.org/Calendar).

**Reporting Credits**

**Q. How should CME credit be reported to the AOA?**

A. For CME activities sponsored by an AOA-Accredited Category 1 CME Sponsor: it is the responsibility of that CME Sponsor to report all CME credit to the AOA. Credits submitted by a physician for such activities will not be accepted by AOA.

For non-osteopathic-sponsored CME activities: it is the physician’s responsibility to report these CME activities to the AOA. A certificate of attendance or a letter of verification from the CME sponsor, along with the physician’s AOA ID number, must be provided.

---

**Foundation for Osteopathic Dermatology Accepting Grant Applications for 2016**

**What is The Foundation for Osteopathic Dermatology?**

The Foundation for Osteopathic Dermatology was founded in 2002 by the AOCD as a unique extension of the Osteopathic Dermatology community. Its purpose is to improve the standards of the practice of Osteopathic Dermatology by raising awareness, providing public health information, conducting charitable events, and supporting research through grants and awards given to those applicants under the jurisdiction of Osteopathic Dermatology Physicians.

**How Does The Foundation for Osteopathic Dermatology receive its Funding?**

Thank you for your interest in helping the FOD. Funding is solely through voluntary donations from physicians and members of the Osteopathic Dermatology community and the generous sponsorship of corporate donors.

To make a tax-deductible donation that supports research, grants and other FOD programs, please send a check or money order to:
Applications must be typewritten or printed and contain all of the following:

1. Curriculum vitae:
   Limited to four pages. Include the following, listed in chronological order: employment, positions and honors, selected peer-reviewed publications (do not include publications submitted or in preparation), research experience.

2. A photo portrait (head and shoulders) of the applicant.

3. Budget:
   A budget detailing how the funds will be used.

4. Research proposal containing the following:
   Introduction: Include description of the general concepts of the project, background information, preliminary work and observations or reference to existing literature.

5. Major Methods:
   A detailed description of the research plan including methods and controls. Include a description of the proposed experiments or procedures; the techniques to be used; the number and type of subjects; the control population; the types of data expected to be generated; and the means by which the data will be analyzed and interpreted.

6. Analysis of Results:
   Provide a description of the significance of this research to the field of dermatology and osteopathic medicine (philosophy or practice) in general.

7. Project Summary
   The summary should provide a concise overview of the project (limited to one page).

Incomplete applications will not be accepted. Applications received after the deadline date will be returned unread.

The FOD Young Investigator Grant is awarded annually to an osteopathic physician with five or more years in practice, who is certified in dermatology and conducting research in dermatology at an accredited institution. The purpose of this grant is to sponsor or co-sponsor research in any area of dermatology.

The FOD Resident Research Grant is awarded annually to an osteopathic dermatology resident in an AOA accredited institution. The purpose of this grant is to foster research in dermatology medicine conducted by dermatologists at a graduate level.

The FOD Young Investigator Grant is awarded annually to an osteopathic dermatologist who is a graduate of an accredited dermatology residency and practicing dermatology in an accredited institution for five years or less. The purpose of this grant is to foster research among young dermatologists and is awarded to promising physician researchers meeting these criteria.

The FOD Institutional Grant is awarded to the institution where an osteopathic dermatologist is currently conducting their clinical or bench research. This research may be clinical, diagnostic and/or therapeutic as it relates to the specialty of dermatology.

Deadline for Submission
Applications must be received by December 31 of each year to be eligible for consideration.

Administrative Information
Applications for research grants are reviewed for validity and efficacy by the Board of Trustees of the Foundation. The Board will determine the selection of grant applicants and the amount of grant monies allocated based on funds available in the grant category.

All applicants will be notified of the receipt of their application within 10 days by the Executive Director.

Applicants receiving grants for any of the programs described in this brochure will receive their grant monies in two or more payments. At the end of the fiscal year, appropriate tax forms such as a 1099 will be sent.

Applicants will be ineligible to apply for subsequent grants for one year after receiving a grant.

Required Reports
Grant recipients are required to submit a report after 6 months and upon completion of the project as well as a full reconciliation of funds dispersed.

All reports should be sent to:
Foundation for Osteopathic Dermatology
P.O. Box 7525
Kirkville, Missouri 63501-7525
Instant gratification.²,†

Introducing Neotensil™ — the only noninvasive solution that reduces the appearance of under-eye bags, within an hour.³,*

Living proof®
neotensil™
daily under-eye reshaping procedure

To order, contact your Obagi sales representative today or call 1.800.636.7546. For more information, visit www.obagi.com.

*Photos have not been retouched. Results may vary.
†Study results for one application of Neotensil in a 16-hour durability study; 4% of patients saw results within 10 minutes and 70% of patients saw results within 1 hour; N=28.
‡Study results for once-daily application of Neotensil in a 2-week pilot study; N=25.


Neotensil and Living Proof are trademarks of Living Proof, Inc. used under license.

Except as otherwise indicated, all other product names, slogans and other marks are trademarks of the Valeant family of companies. Distributed by OMP, Inc.

©2014 Obagi Medical Products, Inc., a division of Valeant Pharmaceuticals North America LLC. DM/NEO/14/0008c 03/14
Title of Project:______________________________________________________________________________

Name of Applicant:______________________________________________________________________________

Mailing Address:______________________________________________________________________________

City, State, Zip:______________________________________________________________________________

EmailAddress:______________________________________________________________________________

Training Status:______________________________________________________________________________

Institution where work will be done:________________________________________________________________

Name of Supervising Physician:_________________________________________________________________

Amount Requested___________________________________________________________________________

Grant Applied for:

_________The FOD Resident Research Grant

_________The FOD Young Investigator Grant

_________The FOD Physician Investigator Grant

_________The FOD Institutional Grant

The undersigned agree: To complete the project as outlined herein and to submit reports as outlined by the Foundation for Osteopathic Dermatology

To make available the results of the studies through normal scientific publication channels, as appropriate, with credits designating the author as a grant recipient offered by the Foundation for Osteopathic Dermatology.

(Signed)___________________________________________________  Date __________________________
Applicant

(Signed)___________________________________________________  Date __________________________
Supervising Physician

Deadline for submission is December 31 of each year.
Foundation for Osteopathic Dermatology
American Osteopathic College of Dermatology
P.O. Box 7525
Kirksville, MO 63501
Fax: 660-627-2623
Office: 660-665-2184 800-449-2623

Become a donor to one of the fastest growing Foundations in Osteopathic Medicine, the Foundation for Osteopathic Dermatology! Through your pledge, the Foundation can achieve its’ goals of providing public health information, funding research and charitable contributions! We can only do it with your support of a tax-deductible donation.

Categories Available:

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pinnacle Table</strong></td>
<td>$25,000 ($5000 per year over a five year period)</td>
</tr>
<tr>
<td><strong>Ulbrich Circle</strong></td>
<td>$10,000 ($1000 per year over a ten year period)</td>
</tr>
<tr>
<td><strong>Koprince Society</strong></td>
<td>$1000</td>
</tr>
<tr>
<td><strong>Leaders of Osteopathic Dermatology</strong></td>
<td>$500</td>
</tr>
<tr>
<td><strong>Scholars Circle</strong></td>
<td>$250</td>
</tr>
<tr>
<td><strong>Residents Forum</strong></td>
<td>$100</td>
</tr>
</tbody>
</table>

___ Yes, I want to help in the FOD Campaign and will pledge $___________ today.

___ Yes, I want to become a member of the Ulbrich Circle and will pledge $1000.00 per year over the next ten years.

___ Yes, I want to become a member of the Pinnacle Table and will pledge $5000.00 per year over the next five years.

Name_________________________________________________________________________

Address_______________________________________________________________________

City, State, Zip Code___________________________________________________________

Telephone (        )__________________    E-mail_______________________________________

Payment Method: _____ check _____ Visa _____ Master Card _____ Amex

Credit Card:__________________________________________  Exp. Date:_______ CV #_____

Signature:__________________________________________ Date:________________

Please mail or fax your pledge to the address above.

Payable for calendar year: January 1 – December 31
Seaside Dermatology seeking a BC/BE dermatologist to join our thriving practice

Located a sea shell’s throw away from the ocean, in Murrell's Inlet, SC, Seaside Dermatology offers an affluent and growing patient base in an ideal setting. Nestled in between Charleston and Myrtle Beach, you have a variety of culture at your fingertips while enjoying the calm pace of beach life. **Medical, surgical and cosmetic dermatology available. Partnership opportunity** for the right fit. We look forward to you joining our team and being a part of our community!

- 4.5 day work week
- Base salary plus bonus structure
- 401k match
- Partnership potential
- Malpractice insurance

Please contact Dr. Gibson if interested at (843) 651-4600 or vlowenbraun@gmail.com. Visit seaside-dermatology.com

Dermatologist transitioning to retirement seeking BE/BC to join busy Michigan practice

Dermatologist wishing to transition into retirement is seeking a BE/BC dermatologist to join his busy general dermatology practice in Madison Heights, MI. This is an independent practice affiliated with a large multi-specialty group. The transition schedule is flexible. An appraisal will help to determine a fair and mutually acceptable buyout agreement. For more information, please contact Dr. Joel Harris at the following email: skinmadhts@aol.com.

Water's Edge Dermatology seeking dermatologist for Sebring, FL office

We are a growing but down to earth dermatology practice. Each of our offices have a homey feel. Once you see one of our offices you will understand our value system. Our front office staff sit behind a wide opening to greet patients as they check in. We don't value closed unwelcoming sliding glass with signs posted to it. All phone calls are answered by a front office person in the office that is being called. We don't value press 1 for this and press 2 for that. We have well trained and pleasant medical assistants in sufficient numbers to make the physician feel he/she can attend to the patient’s needs and do what he/she is trained to do. Wouldn't you like to practice in an environment like this?

If skin cancer is your interest, then please explore this opportunity. Florida is a haven for seniors and a great place for families to live. Sebring, FL is skin cancer heaven. If you want to be busy doing all aspects of dermatology including MOHS, then this is the opportunity for you. For this location we are offering a signing bonus and a very high guaranty against a percentage of collections. Please consider this lovely lakeside community south of Orlando. We will consider repayment of medical student loans. Contact Lewis Bergman at (561) 694-9493 or lbergman@wederm.com.